Abstract

Human relaxin-2 as active ingredient in a pharmaceutical composition for treating a subject exhibiting cachexia syndrome or cardiac wasting or cardiac decompensation. The application also describes methods of treating cachexia, cardiac wasting and patients exhibiting clinical signs of suffering from cardiac decompensation. Further described is a method of using a patch pump for subcutaneous or intravenous infusion of relaxin or human relaxin-2.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61P 9/02 - Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Abstract

Relaxera Pharmazeutische GmbH & Co.KG 36 IDK00257PC 20-Nov-23 SUMMARY. A pharmaceutical composition for daily (q.d.) or twice daily (b.i.d.) subcutaneous injection of a bolus of human relaxin-2 or a complex of relaxin-2 and zinc for a period of at least one week, preferably three to twelve months, and injection pens for treating heart failure with preserved ejection fraction, atrial fibrillation, a patient suffering from diabetes and heart failure with preserved ejection fraction, and/or atrial fibrillation; for producing the protective effects of synthetic human relaxin-2 associated with ischemic heart disease, including the reduction of inflammatory leukocyte and platelet responses, inhibition of the release of proinflammatory and arrhythmogenic mediators by leukocytes and mast cells and other harmful substances generated by inflammation, oxidative stress, and necrosis, for use as a broad-spectrum replacement of glucocorticoids, mineralocorticoids, corticosteroids and their analogues in the treatment of tissue and endothelial injury without inducing gluconeogenesis and cushingoid adverse effects; for supporting the repair of tissue and endothelial injuries by promoting immunosuppressive regulatory T cells (Treg), particularly, in autoimmune pathologies and organ transplantation. Figure 4D

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 47/52 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient

Abstract

Relaxin-2 for use as a broad-spectrum substitute of glucocorticoids, mineralocorticoids, corticosteroids and their analogues for treating tissue and endothelial injuries without incurring inducing gluconeogenesis, Cushing's syndrome and cushingoid adverse effects. Medicament and treatment for supporting the repair of tissue and endothelial injuries by a promotion of immune suppressive regulatory T cells (Treg), particularly, in case of autoimmune pathologies and organ transplantation.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07K 14/64 - Relaxins
• A61P 9/12 - Antihypertensives
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 35/00 - Antineoplastic agents

Abstract

Human relaxin-2 as active ingredient in a pharmaceutical composition for treating a subject suffering from cachexia syndrome or cardiac wasting or suspected of being at risk of suffering from cardiac wasting or cardiac decompensation is described. Also described are methods of diagnosis of cachexia and cardiac wasting and patients suspected of being at risk of suffering from cardiac decompensation. Further described is a patch pump for sc. or iv infusion of relaxin or human relaxin-2.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61P 9/02 - Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure

Abstract

Human relaxin-2 as active ingredient in a pharmaceutical composition for treating a subject suffering from cachexia syndrome or cardiac wasting or suspected of being at risk of suffering from cardiac wasting or cardiac decompensation. The application also described methods of diagnosis of cachexia and cardiac wasting and patients suspected of being at risk of suffering from cardiac decompensation. Further described is a patch pump for sc. or iv infusion of relaxin or human relaxin-2.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• C07K 14/64 - Relaxins

Abstract

A pharmaceutical composition for treatment of persons afflicted of heart failure with preserved ejection fraction (HFPEF), diastolic heart failure (DHF) or diastolic dysfunction (DF), the composition comprising a therapeutically effective amount of a compound capable of specific binding to the relaxin receptor (RXFP1) present on fibroblasts, fibromyoblasts, endothelial cells, endocardial cells, and cardiomyocytes in the cardiac muscle to increase the heart's stroke volume at lower end-diastolic pressure.

IPC Classes  ?

• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61K 38/22 - Hormones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/113 - Multiple emulsions, e.g. oil-in-water-in-oil
• C07K 14/64 - Relaxins
• C07K 14/72 - ReceptorsCell surface antigensCell surface determinants for hormones

Abstract

A pharmaceutical composition for treatment of persons afflicted of heart failure with preserved ejection fraction (HFPEF), diastolic heart failure (DHF) or diastolic dysfunction (DF), the composition comprising a therapeutically effective amount of a compound capable of specific binding to the relaxin receptor (RXFP1) present on fibroblasts, fibromyoblasts, endothelial cells, endocardial cells, and cardiomyocytes in the cardiac muscle to increase the heart's stroke volume at lower end-diastolic pressure.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/113 - Multiple emulsions, e.g. oil-in-water-in-oil
• C07K 14/64 - Relaxins

IPC Classes  ?

• A61K 38/22 - Hormones
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/12 - Antihypertensives
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
• C07K 14/64 - Relaxins

Abstract

A pharmaceutical composition
for treatment of persons afflicted of
heart failure with preserved ejection fraction
(HFPEF), diastolic heart failure
(DHF) or diastolic dysfunction (DF), the
composition comprising a therapeutically
effective amount of a compound capable of
specific binding to the relaxin receptor
(RXFPI) present on fibroblasts, fibromyoblasts,
endothelial cells, eudocardial cells,
and cardiomyoeytes in the cardiac muscle
to increase the heart's stroke volume at
lower end-diastolic pressure.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure